MIT’s Initiative for New Manufacturing builds momentum

In May, the Initiative for New Manufacturing (INM) marked its first anniversary with MIT Manufacturing Week, four days of events that attracted more than 800 registrants including students, faculty, industry leaders, investors, entrepreneurs, and government officials to explore topics ranging from how companies are using AI on factory floors to the role of startups in introducing innovation to new workforce solutions to address the worker shortage.

“INM launched a year ago with the premise that strengthening the industrial base needed a coordinated response, and MIT has a responsibility to lead it,” says Paula T. Hammond, dean of MIT’s School of Engineering and co-chair of INM’s Steering Committee. “The response and participation level has been huge. MIT Manufacturing Week proved that the appetite for change — from students to chief executives — is real and urgent.”

The week opened with a cybersecurity workshop co-led by INM and Google Cloud for the initiative’s industry members. It continued with the MIT MIMO (Machine Intelligence for Manufacturing Operations) symposium focused on deploying artificial intelligence on factory floors, alongside discussions on workforce development, emerging technologies, startups, and industrial transformation. The week closed with a regional research showcase and competition that drew more than 140 graduate students and postdocs from across New England.

Over the past year, INM has also continued its distinguished speaker series featuring manufacturing leaders including Keith Flynn, senior vice president of manufacturing at Anduril; Roland Busch, president and CEO of Siemens; and Venky Alagirisamy, COO of Nike.

Inspiring a new generation of manufacturing startups

A central goal of INM is to help more students see manufacturing as a frontier for scientific discovery, technological innovation, entrepreneurship, and societal impact.

To support that effort, INM is launching and leading programs to help move early-stage ideas and new technologies from the lab to real-world development, and to catalyze new manufacturing companies. 

This year, INM partnered with NSF I-Corps New England, which helps researchers turn their startup ideas into companies, to host its first manufacturing research showcase. More than 140 teams from 17 universities across New England applied to participate. Forty finalist teams received mentorship on their ideas and advanced to the final competition, where eight teams shared $50,000 in prize funding.

The top prize in the category “most transformative innovation” went to MIT PhD student Jake Read for “The End of G Code,” a project focused on modular machine control architectures designed to accelerate the development of new manufacturing equipment and processes. Vatsal Patel from MIT and Joshua Grace from Yale University won the top prize in the research excellence category, for “VisFT,” scalable six-axis force-torque sensors.

Project themes presented by participating teams included AI tools for manufacturing, semiconductor manufacturing and process control, robotics and autonomous assembly, digital twins and simulation, new materials, additive manufacturing, next-generation shipbuilding, and biomanufacturing. 

“Entrepreneurship is a transformative pathway to take research to market, and to drive faster innovation and scale-up,” says John Hart, INM faculty co-director and head of MIT’s Department of Mechanical Engineering. “At INM’s inaugural research showcase, we had tremendous interest from universities across New England, along with enthusiastic participation from industry, investors, and experienced founders across the ecosystem. We are excited to build on this success and work toward a nationwide program and platform for entrepreneurship and translation in manufacturing.” 

The Cheng Wu Foundation supported the showcase. 

Growing industry membership

During MIT Manufacturing Week, First Solar became INM’s eighth industry member, joining Amgen, Autodesk, GE Vernova, Flex, PTC, Sanofi and Siemens. 

The growth of INM’s consortium reflects a broader recognition that the challenges facing modern manufacturing — from supply chain resilience to workforce development and industrial competitiveness — are too complex for any single sector or company to address alone. 

This reflects renewed interest in manufacturing at a moment when advances in artificial intelligence, robotics, energy systems, and advanced materials are transforming industrial production. INM provides a platform to convene and provide solutions.

INM’s industry consortium model brings industry, researchers, and educators together around shared manufacturing challenges, with a focus on emerging technologies, workforce transformation, and commercialization pathways. Members participate in workshops and working groups on topics including cybersecurity and digital twins, implementing automated systems, AI agents in regulatory environments, and AI and continuous innovation. INM helps them connect with students, meet with startups, and learn from one another.

“Our members see MIT as a partner that can help them both address today’s challenges and think far into the future,” says Rick Locke, dean of the MIT Sloan School of Management and co-chair of INM’s steering committee. “This kind of multi-industry engagement is unusual and powerful.”

A year of rapid progress

When MIT launched INM a year ago, the goal was to create stronger connections between research, industry, workforce development, and entrepreneurship — helping accelerate how new manufacturing technologies move from the laboratory into real-world development.

Since then, the initiative has expanded quickly across research, industry, workforce training, and student engagement. INM issued a call for proposals focused on artificial intelligence and automation, receiving an incredible response from faculty and researchers, and funding eight seed research projects. In June, the initiative plans to publish eight white papers as part of a broader study examining the future of manufacturing. 

During MIT’s Independent Activities Period (IAP) in January 2026, INM collaborated with NSF I-Corps to guide 13 early-stage teams through customer discovery as part of the I-Corps Spark program.

Workforce development has also been a major focus. This fall, MIT launched the Technologist Advanced Manufacturing Program (TechAMP), led by Principal Research Scientist John Liu, to create a new generation of shop floor leaders and drivers of productivity — becoming“‘technologists” — at six sites across New England, including three community colleges. 

“INM has the potential to transform the national manufacturing workforce,” says Liu. “It will require deep engagement between how people learn and lead, and how firms adopt new technologies and transform. We’re just getting started.” 

INM is now exploring a national rollout of TechAMP, along with expansion into areas including biomanufacturing and semiconductor manufacturing.

On campus, INM supported student engagements including an AI and automation lunch series that Professor Faez Ahmed and colleagues organized, and visited factories through its Factory Observatory program that Ben Armstrong and the MIT Industrial Performance Center led. This spring, students also founded MIT’s first manufacturing club, holding its launch event during MIT Manufacturing Week. “We’re thrilled students are taking the lead,” says Sloan associate professor and INM faculty co-director Karen Zheng. “It was really exciting to see a full room of 80-plus students across campus coming together for the kickoff event during the busiest final period of a semester. This speaks to the students’ enthusiasm.” 

An eye toward the long term

While maintaining a deep focus on strengthening domestic manufacturing, INM aims to have a global reach. For example, the initiative is collaborating with NAMTECH, a new education institute in Ahmedabad, India, where students are now taking an adaptation of MIT’s well-known “yo-yo course,” or 2.008 (Design and Manufacturing II), focused on the fundamentals of manufacturing processes.

Next year, INM plans to bring more manufacturing leaders to campus, offer additional programming for emerging entrepreneurs, graduate the first cohort of TechAMP students, bring TechAMP to new states, grow the consortium to include new industries, and deepen research into manufacturing productivity. 

“INM aims to be a catalyst for transforming manufacturing across the nation to drive innovation, economic growth, and new types of jobs,” says Chris Love, faculty co-director of INM. “MIT’s work on the PIE (Production in the Innovation Economy) study in 2013 highlighted the value of proximity between production and innovation. INM seeks to rekindle this relationship in manufacturing across the country.”

de MIT News https://ift.tt/O4KUenM

Fluorescent nanosensor enables rapid, first-of-its-kind detection of key gut health biomarker

An international team of researchers has developed a novel fluorescent nanosensor powered by carbon nanotubes that is capable of rapidly detecting an emerging biomarker linked to gut health and disease. 

This important development could eventually lead to faster and more accessible gut-health testing. 

Indole-3-propionic acid (IPA) is a metabolite produced by gut bacteria during the breakdown of dietary tryptophan, an amino acid essential for protein synthesis. It plays an important role in regulating inflammation and oxidative stress, and has been associated with conditions such as inflammatory bowel disease (IBD), Type 2 diabetes, and liver disease. However, current detection methods rely on traditional mass spectrometry-based analytical techniques, which are costly and time-consuming, making it impractical for routine screening or point-of-care use.

The new platform addresses a longstanding gap in gut metabolite sensing. Using a fluorescence-based approach, the sensor produces a rapid optical readout within minutes, offering a significantly faster and more accessible alternative to conventional analytical techniques. It demonstrates high selectivity, distinguishing IPA from closely related metabolites commonly found in the gut, which enables accurate detection even in complex biological environments such as blood serum.

“This is the first time we are able to directly and rapidly measure IPA levels in biological samples using an optical nanosensor,” says co-first author Mervin Ang, assistant professor at the National Institute of Education (NIE) within Nanyang Technological University in Singapore, who was also associate scientific director at the Disruptive and Sustainable Technologies for Agricultural Precision (DiSTAP) interdisciplinary research group within the Singapore-MIT Alliance for Research and Technology (SMART) when the research was initiated. “This novel approach, which moves away from traditional mass spectrometry, can pave the way towards faster and more accessible ways of monitoring gut health in real-world settings.”

This latest breakthrough is described in the research team’s open-access paper, “Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring,” in the journal Advanced Healthcare Materials. The work was led by researchers at NIE, MIT, and SMART, in collaboration with clinicians from the National University Hospital (NUH) and Yong Loo Lin School of Medicine within the National University of Singapore (NUS Medicine). 

From monitoring plants to sensing human health

The new nanosensor builds on SMART DiSTAP’s research into nano and optical sensor technologies. Originally developed to monitor plant health — including plant growth signals and stress responses —  the technology has now been adapted for human health applications by redesigning the nano- and optical-sensing platform to detect IPA.

“This work builds on technology at SMART DiSTAP on molecular recognition. We have used techniques like this to measure hormones and metabolites in living plants for agriculture, and have now applied it to the human gastrointestinal system. We were able to apply it to this long-standing challenge in gut health,” says Michael Strano, SMART DiSTAP lead principal investigator, the Carbon P. Dubbs Professor of Chemical Engineering at MIT, and corresponding author. 

“By focusing our molecular recognition on this important gut health biomarker, we’ve demonstrated a powerful new tool that could one day enable proactive, personalized health care. The tool promises near-instant insights into gut wellness, or the status of chronic diseases like IBD.”

A dual-mode platform for rapid testing and future monitoring

A key innovation of the technology is its dual-mode sensing capability. 

The nanosensor operates in both a visible fluorescence mode, enabling rapid, low-cost, high-throughput screening of biological samples; and a near-infrared mode, with wavelengths that can penetrate deeper into tissues. The near-infrared capability, enabled by carbon nanotubes, allows the technology to be adapted for in vivo applications and integration into wearable devices that could be used for home-based testing or continuous monitoring. This could, for example, help patients with chronic conditions like IBD detect flare-ups earlier and manage their health with greater autonomy. 

This flexibility allows the platform to be utilized in various environments, from laboratory tests to hospital bedside use, and wearable devices for real-time health monitoring. 

Validated in patient samples

To evaluate its clinical relevance, the research team collaborated with NUH clinicians to test the nanosensor on 125 human plasma samples across multiple patient groups, including healthy individuals and those with gastrointestinal diseases.

The study revealed significant differences in IPA levels between healthy individuals and patients with inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Patients with active gut inflammation showed lower IPA levels — consistent with established clinical findings.

“From a clinical perspective, having a rapid and minimally complex way to assess metabolite levels like IPA could be very valuable,” says Jonathan Lee, senior consultant in the Division of Gastroenterology and Hepatology within the Department of Medicine at NUH; adjunct associate professor at NUS Medicine; and co-first author of the work. “It has the potential to complement existing diagnostic tools and provide additional insights into patients with inflammatory bowel diseases.”

Faster, more accessible gut health testing

Beyond the laboratory, this research could pave the way for faster and more accessible gut health testing. Instead of relying on complex and time-intensive laboratory methods, the new nanosensor could enable rapid screening in clinics, or even portable or home-based testing, helping to detect gut diseases earlier and monitor treatment progress more easily.

Unlike conventional microbiome tests that focus on identifying which bacteria are present, this nanosensor measures what those microbes are actively producing, offering a more direct and functional snapshot of gut health. Directly measuring metabolite output, rather than bacterial composition alone, could provide more meaningful insights into overall health and support more personalized approaches to health care. 

Beyond clinical diagnostics, the technology can be used to track the immediate efficacy of dietary interventions. Users can see rapidly if specific foods or probiotics are successfully fueling their gut bacteria to produce anti-inflammatory molecules like IPA. The sensor also demonstrated reliable performance in complex biological fluids such as serum and plasma, an important step toward real-world clinical deployment and further translational applications. 

For pharmaceutical and therapeutic research, the nanosensor could be used to conduct rapid functional tests to determine the efficacy of new therapeutics or probiotics. By providing an instant readout of IPA levels, the platform could enable them to demonstrate in real time that their therapeutics are biologically active and effective, significantly accelerating drug screening and dosage optimization processes.

Toward point-of-care diagnostics, and beyond

“The transition from laboratory discovery to a point-of-care clinical tool is already underway,” says Ang. “With further development, the platform has the potential to be translated into clinical applications, and in the long term, adapted into portable platforms for routine health monitoring.”

Looking ahead, the research team has been awarded an Innovation to Startup Innovation Grant to incubate a Singapore proto-startup to advance validation and development. The focus would be to translate the sensor into a point-of-care clinical diagnostic tool, and aim to expand the platform to detect multiple gut metabolites simultaneously and AI-driven signal deconvolution, enabling more accurate, comprehensive and personalized gut health monitoring. 

Future developments may also explore integration into wearable devices, microneedle systems, or microfluidic platforms for continuous, real-time sensing.

The research was supported by the Intra-CREATE Seed Collaboration Grant, and research conducted at SMART was supported by the National Research Foundation Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) program.

de MIT News https://ift.tt/0jJopdr

A tiny ingestible sensor can measure temperature from inside the body

In a hospital or at home, temperatures are usually taken using an oral or forehead thermometer, but these do not always accurately reflect the core body temperature. Measuring core temperature from within the body could make it easier to determine whether someone is sick, and whether they’re at risk of spiking a dangerous fever.

To make it more feasible to obtain core body temperature measurements, MIT engineers have developed an ingestible sensor that can send continuous temperature updates from the GI tract. 

The sensor is shaped like a tiny blueberry, 6 millimeters in diameter and 4 millimeters in height. That makes it much smaller than existing ingestible temperature sensors, which are more difficult to swallow and pose a potential risk of obstructing the GI tract.

“A sensor like this gives us the ability to monitor infections and identify them early,” says Giovanni Traverso, an associate professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, and an associate member of the Broad Institute of MIT and Harvard. “That’s very relevant, particularly for at-risk populations like people who are immunosuppressed from chemotherapy treatments or immunosuppressive drugs.”

Ingestible sensors could also enable more accurate temperature measurements for fertility tracking, and for monitoring people during anesthesia.

Traverso and Anantha Chandrakasan, MIT’s provost and the Vannevar Bush Professor of Electrical Engineering and Computer Science, are the senior authors of the new study. MIT postdoc Saransh Sharma is the lead author of the paper, which appears today in Nature Electronics.

Ingestible electronics

A handful of ingestible temperature sensors have become commercially available in recent years, but most are the size of a multivitamin or slightly larger, making them more challenging to swallow. Their size can also increase the risk of obstructing the GI tract.

Those capsules tend to be large due to the complex circuits they include, which require a great deal of power. That power is provided by relatively large, on-board batteries that make up much of the bulk of the capsule.

The MIT team wanted to design sensors that could measure temperature accurately, but at a much smaller size.

“The reason for them to be small is safety,” Traverso says. “We want something that is so small that the risk of any blockage or obstruction is highly mitigated, and also so that it can be easily ingested.”

To create a smaller device, the researchers set out to reduce the size of all of the main components — the temperature-sensing circuit, the antenna that relays temperature data, and the battery.

For the circuit, they created their own customized circuit that can fit onto a 1-square-millimeter silicon chip. To reduce the chip’s power consumption, the researchers designed an oscillator based on leakage current — the small current that flows through a circuit when it’s off. The frequency of this current varies depending on the temperature of the chip’s surroundings.

This circuit, which can detect temperature with an accuracy of 0.01 degrees Celsius, requires very little power — about 10 nanowatts. This means that it can be powered with a 1.55-volt coin cell battery, which is 4.8 millimeters in diameter and about 1.6 millimeter thick.

The new design further cuts energy consumption by using a communication strategy known as backscattering. This approach allows most of the power requirements to be outsourced to an external antenna that is located outside the body, within a foot or two of the sensor. The external antenna emits an ultra-high-frequency radio wave, which is then modulated by a tiny antenna within the sensor and sent back to the external antenna. By interpreting the changes in the radio wave, the external antenna can calculate the temperature value.

“We combined all of these different pieces together — the silicon chip, the battery, and the antenna — and we made it into an ingestible capsule, which is the smallest ingestible capsule that we have seen for temperature-sensing paradigms,” Sharma says. 

The internal antenna sends out a temperature reading once every second, allowing for continuous monitoring of temperature.

Tiny thermometers

The researchers envision that this kind of sensor could be useful in several scenarios, including monitoring infection and observing patients during and after anesthesia. Anesthesia often disrupts the body’s normal temperature regulation mechanisms, which can put patients at risk of hypothermia.

This type of device could also be used at home, for monitoring fevers in children, or measuring core body temperature as a marker of ovulation, for fertility purposes. It could also be useful for monitoring athletes, soldiers, or anyone else who might be exposed to extreme temperatures. 

To explore these possible uses, the researchers tested the sensors in animals while they were under anesthesia, and found that they could accurately detect and transmit temperature information. They also obtained accurate readings from animals that were awake and actively moving.

The researchers are now working on combining the temperature sensor with other sensors that could measure vital signs such as heart rate. They hope to begin testing these types of sensors in clinical trials within the next few years. 

If proven effective for people in high-risk situations, Traverso believes such sensors could become widely used by anyone who needs to monitor their temperature. 

“I think this could replace all thermometers, because it’s the most accurate way of taking temperature,” he says. “If we have miniature systems that can be easily swallowed and give very accurate data that’s superior to the current data, I think it can be helpful in so many ways.”

Other authors of the paper include Yubin Cai, Injoo Moon, Zhenming Yang, Peter Chai, Niora Fabian, Kailyn Schmidt, Alison Hayward, Andrew Pettinari, Maria Platero, Benedict Laidlaw, and Ashley Guevara.

The research was funded by the 711^th Human Performance Wing, the Defense Advanced Research Projects Agency (DARPA), and the Advanced Research Projects Agency for Health (ARPA-H), which notes that the views and conclusions contained in this article are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States government.

de MIT News https://ift.tt/nO3SNwo

Fact Sheet: Supporting MIT’s Jewish Community

MIT leadership has in the strongest terms rejected antisemitism and taken thoughtful and steadfast action to prevent it, to promote student-wellbeing, to respond to complaints raised by community members, and to address policy violations. 

Some examples of steps MIT has taken to address concerns of antisemitism

• MIT President Sally Kornbluth and other senior leaders have sent multiple campus-wide letters and video messages condemning reports of antisemitism on campus. 
• Prior to October 7, MIT joined the Hillel Campus Climate Initiative, which helps universities build awareness of and take action against antisemitism. Learnings from that engagement continue to guide MIT’s campus response. 
• MIT increased security around campus, including at the Office of Religious, Spiritual, and Ethical Life building, which houses MIT Hillel.
• MIT participated in the Brandeis Leadership Symposium on Antisemitism in Higher Education.
• MIT created multiple opportunities for training, education, and dialogue, e.g.: 
  • American Jewish Committee training on antisemitism for Academic Council, which comprises the Institute’s senior leadership 
  • ADL training on antisemitism for MIT’s Bias Response Team 
  • Institute-level educational programming, including an event featuring Professor Pamela Nadell—director of the Jewish Studies Program at American University and a scholar of antisemitism in America
• The Institute updated, publicized, and enforced its policies on protests and demonstrations and posters/displays.
• MIT provided financial support for two years of weekly lunches focused on supporting MIT’s Jewish community.
• MIT’s leadership provided support for MIT-Kalaniyot, which brings Israel-based faculty and postdocs to MIT with the intent of building and strengthening ties between Israeli researchers and the MIT community.
• The Institute established a cross-functional team with representatives from the Institute Discrimination and Harassment Response Office (IDHR), Office of Student Conduct and Community Standards (OSCCS), Division of Student Life, Human Resources, and the Office of General Counsel to promptly and fairly triage reports of antisemitism and other forms of bias relating to the conflict in the Middle East. 
• Instituted disciplinary proceedings for policy violations stemming from campus protests and related activities, which resulted in significant sanctions for a number of students, including suspensions, expulsions, and numerous individual bans from being on campus, as well as permanent derecognition of a student organization. 
• And MIT established a Title VI coordinator.

Student discipline process improvements

Apart from individual student discipline cases as described above, MIT conducted a holistic review of its student discipline process, which resulted in a number of policy and procedure changes, including: 

• The senior administration has a more direct role in reviewing significant student discipline cases, with the Vice Chancellor for Student Life regularly conferring with the Chair of the Committee on Discipline (COD) and participating in hearing panels in serious cases. 
• The role of the Senior Associate Dean of Student Conduct and Community Standards has been enhanced and elevated, reporting directly to the Vice Chancellor for Student Life. 
• A more streamlined process allows the Chair of the COD to take action in response to noncompliance with previous COD sanctions.
• Additional sanctions were added to the COD Rules, giving the COD a broader range of tools to address student misconduct.
• Enhanced training on discriminatory harassment were made available to COD members. 

Over the last couple years, MIT has experienced a significant decline in the number of reports of student misconduct arising out of allegations of antisemitism or other forms of bias based on religion or ethnic/national origin. 

Courts have dismissed lawsuits claiming antisemitism at MIT

As a result of MIT’s actions, including specifically some of those described above, federal courts have dismissed claims of antisemitic harassment and discrimination asserted against MIT under Title VI. In doing so, the courts have acknowledged the escalating steps MIT has taken to promote a safe, inclusive community for its Jewish community members. For example, in a unanimous decision by the First Circuit Court of Appeals holding that MIT satisfied its Title VI obligations, the Court noted:   

• “As the protest gatherings occurred over the course of seven months, culminating in the Kresge Lawn encampment, MIT took an escalating series of actions aimed at calming the turmoil without violence… Even if we accept plaintiffs' position that some conduct of some protestors was antisemitic, that would not provide a Title VI pretext for requiring MIT to eliminate the protests entirely. In that respect, by managing the situation so as to avoid escalation and violence, MIT was much more effective than plaintiffs claim.” 
• “[A]ny reasonable school administrator in MIT's position could have reasonably surmised that its progressively evolving responses prevented the on-campus conflict from exploding into real violence between October 2023 and May 2024.”

Importantly, MIT took these steps to protect the MIT community even while the Court concluded that much of the campus protest activity at MIT amounted to legally protected expression and not a violation of Title VI: 

• “This absence of consensus reflects ongoing debate as to the relationship between anti-Zionism and antisemitism – debate that our constitutional scheme resolves through discourse, not judicial fiat. Indeed, the debate on occasion has been formal and high profile…We decline to interpret Title VI as arming either side of that debate with the powers of a censor.”

2026 Quality of Life survey results

Below are data from the spring 2026 Quality of Life survey, a community-wide survey administered every two years to better understand the lives of faculty, staff, postdoctoral scholars, and students. The data reflect responses from those who selected “Judaism” as their religion, alone or in part (respondents were able to select more than one religion).

Overall, how satisfied are you being a student at MIT? 
(Percentages are a sum of respondents who selected “very satisfied” + “somewhat satisfied”)

Jewish Undergraduates:
2024: 87%
2026: 97% (compared to 86% for all undergraduate students) 

Jewish Graduate Students:
2024: 78%
2026: 94% (compared to 88% for all undergraduate students)

I feel that I belong at MIT. 
(Percentages are a sum of respondents who selected “strongly agree” or “somewhat agree”)

Jewish Undergraduates
2024: 83%
2026: 92% (compared to 80% for all graduate students)

Jewish Graduate Students 
2024: 70%
2026: 79% (compared to 79% for all undergraduate students)

Notably, not a single Jewish undergraduate respondent in 2026 disagreed with the statement “I feel that I belong at MIT.”

de MIT News https://ift.tt/h3CewL2

Harriet having it all

In winter 1997, at age 60, when many researchers might be looking forward to retirement, Harriet Latham Robinson SM ’61, PhD ’65 was pursuing a faculty position as the chief of microbiology and immunology at the Yerkes National Primate Research Center at Emory University in Atlanta, Georgia. 

She got the job. 

There, she would also co-found GeoVax, a biotechnology company, based on her preclinical research, including work on developing an HIV-1 vaccine. 

Often, as the only woman in a room throughout much of her career, and in the still-developing and male-dominated field of molecular biology, her colleagues were referred to as “doctor” or “professor” at scientific symposia and committee meetings. 

“In contrast,” she recalls, “I was Harriet.”

Becoming a scientist

Robinson was born in 1938, the second of four children, to a mother, Ruth, and a father, Allen, from Ohio and Connecticut, respectively. After finishing grammar school, she attended the Girls’ Latin School, a public magnet school for college-bound young women. Although the school offered only two classes in science — one semester of chemistry and a health class — Robinson credits her time there for inspiring a lifelong love of learning, especially history and languages. 

“At our 50th and 60th high school reunions, I was struck by what my Girls’ Latin school classmates had done with their lives,” she says. “We had become not only wives, mothers, teachers, and nurses we were supposed to become, but also physicians, lawyers, professors, politicians, and businesswomen.” 

Robinson pursued her undergraduate studies at Swarthmore College, where she intended to study political science. After an introductory biology course, however, she switched her major. Despite the shift, a love of languages persisted: Robinson took Russian and, the summer after her senior year of college, served as a Russian-English speaking guide at the 1959 American National Exhibition in Moscow. Despite mounting tensions between the United States and the Soviet Union, she served again in a similar role from September 1961 to January 1962 for a traveling transportation exhibition in Russia and Ukraine, where she was stationed by a Ford Thunderbird, wearing a TWA stewardess uniform.

“We were true entertainment, as well as education, and I worked to do my best to answer questions about America,” she says. “I was most surprised by the pride the Russian people took in the post-World War II accomplishments of their country.” 

Robinson might not have had a career in science at all had it not been for a dean at Radcliffe College who recognized Robinson’s interest in science. Robinson had thought it appropriate, as a young lady, to pursue marriage and to only further her education to become a teacher or nurse. Seeking permission to take chemistry instead of education courses to fulfill requirements for getting a teaching degree, she was referred to a dean who considered it perfectly appropriate for a young woman to pursue another career. Robinson recalls that the dean declared, “My dear, you want to be a scientist.” 

The foundation for a career

Robinson was soon accepted at MIT and was offered a fellowship to teach in an introductory biology lab to help pay her way. She returned from Moscow just five days before the start of a master’s program in biochemistry. In the Department of Biology at MIT, there were only a handful of women, no female faculty, and few ladies’ rooms in 1959. 

It was there that she met Walter “Wally” J.K. Tannenberg, a onetime partner but lifelong friend and companion, an MD taking courses at MIT. He wasn’t “at all taken aback by my becoming an educated woman,” Robinson says. He taught her to ski, and they sailed his lightening, the Ondine, in circles around Robinson’s parents’ comparatively slow motor sailor, the Palometa. 

Their breakup just before the winter holidays in 1963 precipitated her reentry to graduate school, to pursue her thesis work in the lab of Jim Darnell; she threw herself into studies to sit a qualifying exam less than a month after reentry. 

“A Bell Labs physicist who had just joined the Darnell Lab opined that any concept in biology could be mastered in two weeks,” Robinson says. “Much to everyone’s amazement, I not only passed my qualifying exam, but did much better than expected.”

It was at the University of California at Berkeley during her postdoctoral work that she met her husband. Although the marriage would not last the test of time, Robinson and her husband were blessed with three boys, each 13 months apart.

Robinson knew that she wanted to take time away from her career to stay home with her children before they entered primary school. As a graduate student at MIT, to prepare for both having a career and pursuing motherhood, Robinson hired a housekeeper and committed to being in the lab for only a typical 9 a.m. to 5 p.m. workday. If she were to compete with her male counterparts and be with her children, she needed to be able to get things done while working short hours. 

Robinson successfully completed her thesis work in just over two years.

“The difference between bearing children and rising up professional ladders is that you can start up the professional ladder after you are 40,” she advises. “Such is more problematic for having children.”

Robinson’s thesis work at MIT concerned how DNA, which is identical in all cells of an organism, produces different cell types from the same genetic blueprint. She explored this question through the lens of messenger RNA, a gene product that determines which DNA sequences are expressed in a cell. Later, her work on cancer-causing viruses in chickens would help lay the groundwork for gaining insight into genes that can cause tumors to form. 

“In contrast to becoming a wife, becoming a PhD from MIT did not falter, but rather provided me with the foundations for a career I loved in which I used molecular biology and chickens to study the genetic basis of cancer and pioneered the use of DNA as a new method of vaccination,” Robinson says.

Cancer-causing viruses

Robinson, supported by an National Science Foundation fellowship, pursued postdoc training at the University of California at Berkeley, in the lab of Harry Rubin. The Rubin Lab specialized in work on a virus known to cause cancer: the Rous sarcoma virus, which causes rapid tumor onset when introduced into chickens. RNA, it had recently been discovered, was the underlying genetic cause of tumors developing in chickens exposed to the Rous sarcoma virus. It cannot, however, do this deadly work without co-infection with something called a helper virus — in this case, avian leukosis virus. 

Both Rous sarcoma virus and its helper viruses were retroviruses, which can make DNA copies from RNA sequences, a departure from the previously accepted dogma that DNA is only transcribed into RNA, and not the other way around.

Robinson joined the Worcester Foundation for Biomedical Research in 1977, where she continued research on Rous helper viruses and had the opportunity to run her own lab for the first time. In 1998, she was recruited to be a professor of pathology at the University of Massachusetts Medical Center. While there, she conducted pioneering studies on the use of DNA for vaccination and worked on developing an AIDS vaccine. 

In 1999, she moved again, this time to step into the role of chief of microbiology and immunology at the Yerkes National Primate Research Center at Emory University, where she began testing her candidate HIV vaccines in primates. While at the University of Massachusetts and Emory, Robinson and her lab used DNA vaccines, both with and without a poxvirus booster vaccine provided by Bernie Moss at the National Institutes of Health, to immunize animals against influenza, HIV, measles, and Ebola.

“From the early days of DNA vaccines, I had wanted to start a company to help move DNA vaccines from bench to bedside,” she says. 

Thus, GeoVax, short for “Georgia Vaccines,” was born. Robinson co-founded it with Don Hildebrand in 2001 after her move to Yerkes; Robinson would serve as chief scientific officer and a member of the board of directors during her tenure at the company. 

GeoVax successfully moved Robinson’s candidate AIDS vaccine into human clinical trials. These trials were stopped due to the generally poor performance of HIV vaccines in clinical trials, compared to the outstanding therapeutic potential of more recently developed anti-HIV drugs. GeoVax, however, continues to work on vaccines for Mpox, Covid-19, and Ebola, and has expanded its scope to include a cancer treatment.  

A well-deserved retirement 

After rounds of good-natured roasting from colleagues at Emory University and GeoVax, Robinson retired and has been enjoying returning to Palo Alto, California, where her oldest son, Bill, and his wife now live. 

Ultimately, Robinson hopes that her story can encourage everyone, especially young women, not to let pursuing a challenging and enriching career prevent them from realizing the dream of having a family.

“I have had a wonderful life, far exceeding what I ever could have anticipated,” Robinson says. “I have had international adventure, the romance of a man who truly loved me, the joy of motherhood, and the warmth, wonder, and adventure of family and friends, and last, but not least, the exhilaration of a career in molecular biology.”

de MIT News https://ift.tt/2PD70XC

MIT engineers find a way to deliver drugs directly to the esophagus

There are few treatment options available for people with disorders of the esophagus. Delivering drugs directly to this part of the body is difficult, so patients are usually treated with systemic drugs, which can have unwanted side effects.

To overcome that challenge, MIT engineers developed a gel-like oral drug formulation that can coat the mucosal lining of the esophagus after being swallowed, allowing drugs to pass through the tissue.

The formulation, which includes a hydrogel and other key ingredients that promote rapid drug absorption, could be used to deliver antibodies including infliximab, used to treat a number of autoimmune diseases, or other types of antibodies or small-molecule drugs.

“There are many people with esophageal disease, and if you look at drugs for these conditions, they’re very limited in their ability to target this part of the body and it’s very difficult to develop them. We hope this platform will make it easier to develop systems that can help patients suffering from these conditions,” says Giovanni Traverso, an associate professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, and an associate member of the Broad Institute of MIT and Harvard.

Traverso is the senior author of the new study, which appears today in Nature Biomedical Engineering. Former MIT postdoc Christina Karavasili, now an assistant professor at Aristotle University of Thessaloniki in Greece, is the paper’s lead author.

Direct delivery

One of the most common disorders of the esophagus is eosinophilic esophagitis, a type of inflammation that is caused by food allergies and leads the esophagus to close up, making it impossible to swallow food. Crohn’s disease can also cause inflammation of the esophagus. 

These disorders are usually treated with systemic drugs, including infliximab, an antibody that neutralizes an inflammatory protein called tumor necrosis factor alpha (TNF-alpha). However, this drug is an immunosuppressant that can lead to a higher risk for infections and other health problems.

Delivering the drug directly to the esophageal tissue could reduce those side effects, but this is inherently challenging because drugs taken orally pass through the esophagus so quickly. Adding to the difficulty, the esophagus is lined by a layer of tissue called stratified squamous epithelium, which is very impermeable to drugs.

Injecting drugs into the esophageal tissue is another option, but that is uncomfortable for patients and inconvenient because it has to be done at a doctor’s office. There is also at least one anti-inflammatory steroid drug that is formulated as a thick mixture, allowing it to remain in the esophagus longer after being swallowed, but the drug still has some difficulty passing through the impermeable squamous layer.

In this study, the researchers set out to develop new drug formulations that would include molecules that could increase the permeability of those esophageal cells, allowing more of the drug to pass through. 

To identify molecules that would enhance permeability, the researchers designed a screening system that mimics the structure of the esophagus. This system contains esophageal tissue pressed between two vertical plates. Drug formulations can be poured into the top of the system, simulating oral ingestion. The researchers can then measure how much of the drug passes through the tissue and is collected by wells in one of the plates.

Using this system, the researchers were able to measure how different excipients — inactive ingredients that help enhance drug effects — affect the permeability of the esophageal tissue. First, they tested about 100 different compounds and identified several top candidates. Then, they tested pairs of these excipients and found that the most effective combination was a pair of bile salts called sodium chenodeoxycholate and sodium cholate.

These salts appear to work together to loosen up the cell-cell junctions that normally act as a barrier to drug molecule entry. The researchers added those bile salts to a polysaccharide-derived hydrogel, which has a viscous consistency that allows it to lightly coat the lining of the esophagus.

“The hydrogel helps the formulation remain on the esophageal surface for longer, while the bile salts help increase transport across the tissue,” Karavasili says. “Our data suggest that the bile salts temporarily loosen these cell–cell junctions, mainly by interacting with calcium ions that help maintain junction integrity. This creates a more permissive pathway between the cells, allowing larger molecules to move into the mucosal tissue more efficiently.”

Minimizing side effects

In tests in animals, the researchers showed that this formulation could be used to effectively deliver infliximab to the esophagus. They also found that the loosening of the cell-cell junctions was temporary, and the cells returned to normal within three days.

This kind of delivery could help to avoid the side effects that patients sometimes experience when infliximab is given systemically, the researchers say. 

“We were interested in delivering anti-TNFs as a model drug, but also to help people who suffer from conditions like Crohn’s disease to have options that could be delivered to the site,” Traverso says. “If we have the possibility of site-directed delivery, we may be able to mitigate systemic side effects from these immunosuppressing agents.”

The researchers are now working on further optimizing the formulation for potential testing in humans. One key goal is to ensure that the gel adheres for long enough to deliver the drugs, but not so long as to cause discomfort for patients. The researchers are also exploring the possibility of using this approach to deliver other types of drugs. 

“This is a platform to enable the development of drug-delivery systems for the esophagus, which hasn’t been possible before because the tools haven’t existed,” Traverso says.

The research was funded by the Karl van Tassel Career Development Professorship, the Department of Mechanical Engineering at MIT, the Division of Gastroenterology at Brigham and Women’s Hospital, and the U.S. Advanced Research Projects Agency for Health (ARPA-H), which notes that the views and conclusions contained in this article are those of the authors and should not be interpreted as representing the official policies of the United States government.

de MIT News https://ift.tt/QY4xJAz

The long history of vaccine hesitancy

Debates about vaccines are a recurring feature of contemporary politics. It turns out they actually date back more than 200 years, since the development of the first smallpox vaccine. MIT Professor Thomas Levenson, one of the country’s leading science writers, explores this important history in a new book about the contours of anti-vaccination thought. Levenson identifies different types of arguments vaccination opponents have developed through history, to help shed light on our current debates. He spoke with MIT News about his new book, “A Pox on Fools: The True Believers, Grifters, and Cynics Who Convinced Us to Reject Vaccines,” published this week by Penguin Random House. 

Q: Your book is about the longer history of anti-vaccination arguments. How far back does this go, and what have those arguments been? 

A: Hesitation, skepticism, and outright opposition to vaccines is not a new thing. It didn’t just happen starting in the late 1990s. Opposition to vaccines dates back to the beginning of the vaccine era, around the early 19th century. The first kind of opposition to vaccines is this sense that it violates the moral or the natural order. If you believed that God has authority over all of us and is mindful of everything, intervening in the disease process could seem blasphemous. 

In the early 19th century, the first true vaccine, the smallpox vaccine, used material from a related disease, cowpox, that doesn’t cause human beings to fall ill but does provide immunity to smallpox. That shifted the initial focus on God’s plans to the notion that vaccination — sticking some cow-stuff into people — violated the natural order. That sort of uneasiness is easily co-opted by a broader philosophy that says: If you align yourself with nature, you don’t need to use vaccines. 

I want to emphasize that in the early history of the anti-vaccine movement, there were reasonable fears being expressed. That changes over time, because science advances and the mystery of vaccines falls away. Still, the current anti-vaccine movement includes an impulse we all have: We wish to be in control. I would never deny the value of exercise, sunlight, and sanitation, but they are not sufficient when you are faced with many pathogens, and that’s what the modern anti-vaccine movement obscures. We share this world with bacteria and viruses that do their thing no matter what we eat or how much we exercise. 

Q: One section of your book explores the argument that vaccines have been actively harmful. What is that historical trajectory like? 

A: The idea that vaccines are not just unnecessary but actively bad for you is certainly very contemporary, but it too goes back to the beginning of the vaccine era. The first true smallpox vaccine came into public use in 1798. Very soon afterward people started pointing to different harms. Most of them were spurious. They were just making things up or mistaking another infection that was already there. But there were some flaws in the early forms of vaccination. People thought it conferred life-long immunity, and that wasn’t always the case. Additionally, people mistook syphilis infections for cowpox infections and transmitted syphilis to healthy people. There were maybe 750 cases in Europe.

What is repeated over and over in the history of vaccination is that when problems became apparent, people found a way to address them. A problem with diphtheria antitoxin at the turn of the century led directly to the first U.S. regulatory body, the Division of Biological Controls. And when the first polio vaccine was released to the public in 1955, one of the five drug companies making it had shoddy production practices. Thousands got sick, a hundred died, and some were paralyzed. The flawed vaccine was identified after two weeks on sale and stopped cold, and that ended that particular problem. What came out of it was the development of an FDA vaccine division with teeth. 

This is an area where the rhetorical skill of the anti-vaccine movement is on display. Anything human beings do carries some risk. Anything you do medically. I had my hip replaced last year. That carries some risk, such as surgical site infections. Well, the risks of vaccines are incredibly small. The most common response is a sore arm the next day, and maybe feeling under the weather. There is extremely close control over manufacturing now. We have stories of great harm, but the various specific allegations of the last 30 or 35 years have proven to be incorrect. But there’s a power to an anecdote versus statistics. 

Q: This book raises an issue also explored in your last one, “So Very Small,” that the sheer success of vaccines has, paradoxically, created a situation in which people take their effects for granted and find it easier to argue against them. Can you explain this phenomenon?

A: The reason that occurs is because vaccines have worked so brilliantly well. At the turn of the century, life expectancy was much lower, 47 years in the U.S. Several top causes of death were infectious diseases, and child mortality was high. Now, life expectancy is around 80 years in every developed nation, and child mortality is a tiny fraction of 1 percent. By 1970, you had almost a complete set of vaccines against what used to be called childhood diseases. And those diseases, up until extremely recently, had essentially disappeared. And that’s amazing. 

In the 1950s, before the measles vaccine, for instance, everybody had an experience of what it meant to be at at the mercy of waves of infection. But by the 1970s, that was no longer the expected, ordinary, common experience of raising kids. So we’ve forgotten how unpleasant even an ordinary case of one of these diseases is that you recover from, much less the more severe problems and death. In 1952, there was the largest polio outbreak in U.S. history, and it was scary to let your kid go to the movies or a swimming pool. They could go to someone’s birthday party, come back, and two weeks later start feeling muscle aches and a fever, and two weeks after that were maybe paralyzed, or dead. Then in 1955 the Salk polio vaccine came out. We don’t live that way any more. 

And so, because infectious disease seems like a nonexistent threat, vaccines, even with a tiny potential of harm, are made to seem worse because we don’t realize what happens if we let our vaccine coverage lapse. Well, we’re starting to get a glimpse of it, because the measles rate in the U.S. is shooting up, and we see what happens when vaccine coverage wanes, and in particular, when we lose herd immunity. In every population, some people cannot be vaccinated: infants who are too young, some people who have had transplants and are on immunosuppressive drugs, or the elderly in whom sometimes immunity wanes. Some diseases are so infectious, and measles is famous for this, that about 95 percent of a population must be vaccinated or the disease spreads. If we’re not at that threshold, every newborn is at risk. 

We don’t know what it’s like to live with the genuine risk and fear of those diseases. If you were born in 1970, you’re 56 now, and you literally never lived in a world where these diseases were common. 

Q: One source of resistance to vaccines is not strictly medical, but political and philosophical at one level. This also has a lengthy history, it seems. 

A: Another major theme of the anti-vaccination movement is to argue the question: Who has the right to say that somebody else must put something in their body? Again, all this is not new: In the mid-19th century, in the United Kingdom, there was a requirement that children be vaccinated against smallpox, and these mandates brought immediate opposition as an infringement of liberty. 

In 1850 the country’s top doctor, John Simon, physician to the privy council in England, described the right that people claim against vaccination as the liberty of “omissional infanticide,” that you are killing kids by not protecting them. Where do I stand? This is a philosophical question. Does the state have the right to make me do something because it will make society as a whole safer? I think, “Yes.” We live in societies, we depend on each other for all kinds of things, we aren’t just atomized individuals. But I can understand those who say, “No.” I just think it’s wrong. But it’s an argument that’s winning in some places. What I realized as I worked on this book is that the argument against vaccination on philosophical grounds is a lonely view: I owe nothing to anyone, and nothing owes anything to me. I think it’s a fearful one, too.

Q: For the vaccine hesitant, for those questioning vaccines, what will they get out of this book? 

A: On social media you see some people calling vaccine-hesitant people stupid, but that’s not right. People are busy. We all have daily lives. Get the kids ready for school, pack their lunches, go to work, get home, fix dinner. All of us offload some decisions to people we trust as experts. I have a ton of sympathy and empathy both for people trying to think how to make it through an incredibly complicated world. They hear noise about how vaccines are problematic and there’s no easy way for them to get to the bottom of the issue. That’s an opening the anti-vaccine movement exploits.

I hope my book reaches people who are vaccine hesitant. It’s understandable that people might think that where there’s smoke, there’s fire. But when you get down to the bottom question: Do vaccines help human flourishing, do they support the ability of human beings to live healthy, fulfilled lives? Yes, they do. Unequivocally, they are the greatest lifesaving invention humankind has ever come up with.

de MIT News https://ift.tt/MFmhHV1